End-of-day quote
Dhaka S.E.
06:00:00 2024-04-24 pm EDT
|
5-day change
|
1st Jan Change
|
12.2
BDT
|
-2.40%
|
|
-15.28%
|
-36.79%
|
Fiscal Period: June |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
8,110
|
5,758
|
6,574
|
2,951
|
4,391
|
5,159
|
Enterprise Value (EV)
1 |
8,157
|
6,309
|
7,717
|
4,966
|
7,129
|
7,773
|
P/E ratio
|
14.6
x
|
6.98
x
|
9.23
x
|
-52.7
x
|
115
x
|
199
x
|
Yield
|
-
|
-
|
0.73%
|
-
|
0.27%
|
0.12%
|
Capitalization / Revenue
|
3.81
x
|
2.67
x
|
2.72
x
|
2.26
x
|
2.41
x
|
3.09
x
|
EV / Revenue
|
3.83
x
|
2.93
x
|
3.19
x
|
3.8
x
|
3.91
x
|
4.65
x
|
EV / EBITDA
|
7.13
x
|
5.18
x
|
5.1
x
|
5.47
x
|
7.01
x
|
7.36
x
|
EV / FCF
|
-28.5
x
|
-6.83
x
|
-11.3
x
|
-6.22
x
|
-7.84
x
|
16,232
x
|
FCF Yield
|
-3.51%
|
-14.6%
|
-8.86%
|
-16.1%
|
-12.8%
|
0.01%
|
Price to Book
|
2.07
x
|
1.22
x
|
1.23
x
|
0.56
x
|
0.83
x
|
0.97
x
|
Nbr of stocks (in thousands)
|
239,937
|
239,937
|
239,937
|
239,937
|
239,937
|
239,937
|
Reference price
2 |
33.80
|
24.00
|
27.40
|
12.30
|
18.30
|
21.50
|
Announcement Date
|
11/23/17
|
11/8/18
|
4/3/21
|
4/3/21
|
12/2/21
|
12/15/22
|
Fiscal Period: June |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
2,129
|
2,156
|
2,419
|
1,308
|
1,821
|
1,672
|
EBITDA
1 |
1,144
|
1,217
|
1,514
|
907.5
|
1,018
|
1,056
|
EBIT
1 |
825.3
|
772.1
|
907.8
|
148
|
113.3
|
108.8
|
Operating Margin
|
38.77%
|
35.82%
|
37.53%
|
11.32%
|
6.22%
|
6.51%
|
Earnings before Tax (EBT)
1 |
737.6
|
641.7
|
712.7
|
-55.16
|
57.76
|
48.59
|
Net income
1 |
553.9
|
825.4
|
711.9
|
-56
|
38.28
|
25.91
|
Net margin
|
26.02%
|
38.29%
|
29.43%
|
-4.28%
|
2.1%
|
1.55%
|
EPS
2 |
2.308
|
3.440
|
2.967
|
-0.2334
|
0.1595
|
0.1080
|
Free Cash Flow
1 |
-286
|
-924.3
|
-683.7
|
-797.9
|
-909
|
0.4789
|
FCF margin
|
-13.43%
|
-42.88%
|
-28.26%
|
-61%
|
-49.91%
|
0.03%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
0.05%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
1.85%
|
Dividend per Share
|
-
|
-
|
0.2000
|
-
|
0.0500
|
0.0250
|
Announcement Date
|
11/23/17
|
11/8/18
|
4/3/21
|
4/3/21
|
12/2/21
|
12/15/22
|
Fiscal Period: June |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
47.5
|
551
|
1,143
|
2,014
|
2,738
|
2,615
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.0416
x
|
0.4527
x
|
0.7547
x
|
2.22
x
|
2.691
x
|
2.475
x
|
Free Cash Flow
1 |
-286
|
-924
|
-684
|
-798
|
-909
|
0.48
|
ROE (net income / shareholders' equity)
|
14.9%
|
19.1%
|
14.1%
|
-1.06%
|
0.73%
|
0.49%
|
ROA (Net income/ Total Assets)
|
10%
|
7.96%
|
8.04%
|
1.18%
|
0.84%
|
0.76%
|
Assets
1 |
5,541
|
10,369
|
8,849
|
-4,728
|
4,551
|
3,396
|
Book Value Per Share
2 |
16.30
|
19.70
|
22.30
|
21.80
|
22.00
|
22.10
|
Cash Flow per Share
2 |
3.250
|
3.570
|
2.010
|
0.9100
|
0.7900
|
2.400
|
Capex
1 |
1,042
|
1,239
|
1,476
|
1,426
|
578
|
209
|
Capex / Sales
|
48.96%
|
57.46%
|
61%
|
109.01%
|
31.75%
|
12.48%
|
Announcement Date
|
11/23/17
|
11/8/18
|
4/3/21
|
4/3/21
|
12/2/21
|
12/15/22
|
|
1st Jan change
|
Capi.
|
---|
| -36.79% | 26.66M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|